Overactive Bladder Clinical Trial
Official title:
Comparison of the Effects of External Electrical Stimulation Protocols in Women With Overactive Bladder
The aim of our study is a comparison of the effects of external electrical stimulation protocols in women with overactive bladder (OAB).
Status | Not yet recruiting |
Enrollment | 40 |
Est. completion date | February 1, 2024 |
Est. primary completion date | June 1, 2023 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Being in the age range of 18-65 , - Having diagnosed with OAB, - Being a volunteer Exclusion Criteria: - Being pregnant, - presence of severe pelvic organ prolapse, - malignant disease, - urinary infection, - neurological disease, - have electronic and metal implant, - loss of sensation, - lumbosacral peripheral nerve lesion |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Ankara Yildirim Beyazit University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overactive bladder symptoms | Overactive bladder symptoms will be assessed with the Overactive Bladder-V8 Questionnaire | change from baseline at 3 weeks and 6 weeks | |
Secondary | Urgency severity | Urgency severity will be assessed with Patients' Perception of Intensity of Urgency Scale | change from baseline at 3 weeks and 6 weeks | |
Secondary | Bladder functions | Bladder functions will be assessed with voiding diary | change from baseline at 3 weeks and 6 weeks | |
Secondary | Life quality | Life quality will be assessed with the King's Health Questionnaire | change from baseline at 3 weeks and 6 weeks | |
Secondary | Strength of pelvic floor muscle | Strength of pelvic floor muscle will be assessed with Modified Oxford Scale | change from baseline at 3 weeks and 6 weeks | |
Secondary | Perception of recovery | Perception of recovery will be assessed with a 4-point Likert scale | change from baseline at 3 weeks and 6 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04578899 -
"The Effectiveness of Transvertebral Magnetic Neuromodulation in Patients With Detrusor Overactivity"
|
N/A | |
Active, not recruiting |
NCT03556891 -
Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence
|
N/A | |
Not yet recruiting |
NCT05977634 -
Transcutaneous Tibial Nerve Stimulation for Idiopathic Overactive Bladder
|
N/A | |
Completed |
NCT01955408 -
Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment
|
N/A | |
Recruiting |
NCT06201013 -
Efficacy and Safety of Vitamin D in the Treatment of OAB-wet in Children
|
N/A | |
Recruiting |
NCT03727711 -
TPTNS: Home vs Hospital Treatment for Overactive Bladder
|
N/A | |
Completed |
NCT00768521 -
A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)
|
Phase 1 | |
Completed |
NCT03625843 -
Mindfulness Exercises to Reduce Anxiety and Pain During Urodynamic Testing
|
N/A | |
Completed |
NCT02211846 -
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder
|
Phase 1 | |
Completed |
NCT02835846 -
Investigation of the Effect of the Female Urinary Microbiome on Incontinence
|
Phase 4 | |
Completed |
NCT02857816 -
PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB
|
N/A | |
Completed |
NCT02202031 -
Controlling Urgency Through Relaxation Exercises
|
N/A | |
Withdrawn |
NCT02320201 -
Foot Neuromodulation for Overactive Bladder in Children
|
N/A | |
Not yet recruiting |
NCT01423838 -
Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder
|
Phase 4 | |
Not yet recruiting |
NCT01409512 -
Evaluation of Autonomic System Before and After Anticholinergic Treatment in Women With Overactive Bladder
|
N/A | |
Completed |
NCT01458197 -
A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder.
|
Phase 2 | |
Completed |
NCT01437670 -
Observational Study to Estimate the Dry Mouth in OAB Patients With Solifenacin
|
N/A | |
Terminated |
NCT01758848 -
Physical Therapy for Overactive Bladder
|
N/A | |
Withdrawn |
NCT01210859 -
Effects of Antimuscarinic Drugs on Overactive Bladder (OAB) Symptoms After Insertion of Ureteral Stents
|
N/A | |
Completed |
NCT00910845 -
Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
|
Phase 3 |